In this episode of EHA Unplugged, Prof Marion Subklewe discusses one major challenge facing CAR T-cell therapy in Europe: ensuring that eligible patients are referred for treatment. She explains how access has improved since the first CAR T-cell approvals, but highlights that many eligible patients still do not receive these potentially curative therapies. The discussion explores differences between European healthcare systems, barriers to referral, and persistent misconceptions about patient eligibility.
Prof Subklewe advocates for structured referral pathways and multidisciplinary boards that assess all eligible patients in collaboration with CAR T-cell experts. She argues that treatment eligibility should not depend solely on individual physicians and highlights the benefits of coordinated networks, shared decision-making, professional education, and patient engagement.
Listen now for insights into how stronger referral systems could help more patients access CAR T-cell therapy across Europe.
This podcast episode is supported by Bristol Myers Squibb.
Guests: Prof Marion Subklewe
Affiliation:
LMU – University Hospital, LMU Munich
Department of Hematology/Oncology
LMU- Gene Center Munich
Laboratory of Translational Cancer Immunology
Germany
Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
